Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of Anesthesia by Miller, Mark A. et al.
Visualization of Murine Intranasal Dosing Efficiency
Using Luminescent Francisella tularensis: Effect of
Instillation Volume and Form of Anesthesia
Mark A. Miller
1*, Jennifer M. Stabenow
1, Jyothi Parvathareddy
1, Andrew J. Wodowski
1,
Thomas P. Fabrizio
1,2, Xiaowen R. Bina
1, Lillian Zalduondo
1, James E. Bina
1
1The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America, 2St Jude Children’s Research Hospital, Memphis, Tennessee, United
States of America
Abstract
Intranasal instillation is a widely used procedure for pneumonic delivery of drugs, vaccine candidates, or infectious agents
into the respiratory tract of research mice. However, there is a paucity of published literature describing the efficiency of this
delivery technique. In this report we have used the murine model of tularemia, with Francisella tularensis live vaccine strain
(FTLVS) infection, to evaluate the efficiency of pneumonic delivery via intranasal dosing performed either with differing
instillation volumes or different types of anesthesia. FTLVS was rendered luminescent via transformation with a reporter
plasmid that constitutively expressed the Photorhabdus luminescens lux operon from a Francisella promoter. We then used
an IVIS Spectrum whole animal imaging system to visualize FT dissemination at various time points following intranasal
instillation. We found that instillation of FT in a dose volume of 10 ml routinely resulted in infection of the upper airways but
failed to initiate infection of the pulmonary compartment. Efficient delivery of FT into the lungs via intranasal instillation
required a dose volume of 50 ml or more. These studies also demonstrated that intranasal instillation was significantly more
efficient for pneumonic delivery of FTLVS in mice that had been anesthetized with inhaled (isoflurane) vs. parenteral
(ketamine/xylazine) anesthesia. The collective results underscore the need for researchers to consider both the dose volume
and the anesthesia type when either performing pneumonic delivery via intranasal instillation, or when comparing studies
that employed this technique.
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Introduction
Intranasal instillation is currently the most widely used method
for delivery of drugs, vaccines, or pathogen challenges targeted for
either the upper respiratory tract (URT) or lungs of research mice.
Intubation is an alternative method [1,2,3,4,5,6,7] that allows for
very efficient delivery of materials into the lungs, but the
procedure is technically much more demanding and more time-
consuming than intranasal administration. In addition, intubation
includes a much higher risk of injury to the animal that could
compromise the study. Aerosol administration via a nebulizer-
based device [8,9,10,11] also offers very efficient delivery of
materials to the lungs with little risk of injury to the animal;
however, this method is technically demanding and requires
expensive equipment that is not widely available. Moreover, the
use of aerosol generators for studies involving dangerous
pathogens involves safety issues for research personnel that do
not exist when using the intranasal delivery method. In light of
these factors, it seems certain that intranasal administration will
continue to be the most popular method for pneumonic instillation
for the foreseeable future. Surprisingly, there is a paucity of
published literature describing the efficiency of intranasal
instillation of drugs, vaccines, or infectious agents. Therefore, an
analysis of the efficiency of pneumonic delivery via intranasal
instillation that would allow for standardization of the two most
critical variables associated with this technique, namely dose
volume and type of anesthesia, would be of great benefit to
researchers working with murine models.
Francisella tularensis (FT) is a gram-negative facultative intracel-
lular bacterium that causes a high morbidity/mortality zoonotic
disease known as tularemia. FT is one of the most virulent
bacterial pathogens in humans, as evidenced by its published LD50
of less then 10 CFU [12,13]. Because of its high infectivity and the
relative ease with which if can be disseminated via the aerosol
route, FT is considered to have high potential for use as a
biological weapon. The Francisellaceae family of bacteria has a single
genus, Francisella, which has been divided into two species:
Francisella philomiragia (a muskrat pathogen) and Francisella tularensis.
F. tularensis has been further subdivided into four subspecies:
tularensis (type A), holarctica (type B), novicida, and mediasiatica [14].
Of these, only subsp. tularensis and subsp. holarctica cause disease in
humans [15]. The live vaccine strain (LVS) of FT (FTLVS) is an
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candidate in the former Soviet Union [16]. While FTLVS is highly
attenuated in humans, it remains virulent in mice and causes a
tularemicdisease syndromesimilarto that observed inhumans [17].
Technological advances in small animal imaging have made it
possible to monitor in real-time the growth and dissemination of
fluorescent or bioluminescent bacteria in individual animals over
the entire course of infection, offering a powerful alternative to
traditional methodologies. Bioluminescence has proven to be
particularly useful for this application. We recently created a novel
bioluminescence reporter vector (pXB173-lux) that encodes the P.
luminescens lux operon downstream of the FT Pgro promoter. The
lux operon contains genes that are required for production of both
luciferase and luciferin, and transformation of FTLVS with this
vector causes the bacteria to constitutively produce light during in
vitro or in vivo growth [18]. In this report, we employed an IVIS
Spectrum whole-animal live imaging system, coupled with
bacterial load determinations, to evaluate in real-time the
efficiency of intranasal instillation for initiation of lower respiratory
tract (LRT) infections in mice. The results presented here provide
striking visual evidence that both the instillation volume and the
type of anesthesia used during instillation have a significant impact
on the efficiency of pulmonary delivery of FTLVS.
Results
To evaluate the efficiency of intranasal administration for
delivery of FT to the lungs, BALB/c mice (5/group) were
anesthetized with inhaled isoflurane and then challenged with
1610
6 CFU of FTLVS bearing a luminescent reporter vector
(pXB173-lux, Figure 1, see [18]) in a total volume (PBS) of either
10 ml, 20 ml, 50 ml, or 100 ml. Each mouse was subjected to live
whole animal luminescent imaging using an IVIS Spectrum
imaging system beginning 24 hours post-challenge (Figure 2A).
The imaging studies revealed a clear difference in luminescent
signal from the lungs that correlated with the dose volume used for
intranasal instillation. While very little luminescent signal was
observed emanating from the lungs of mice challenged using a
10 mlo r2 0ml dose, the mice that were dosed using the larger
instillation volumes (50 ml or 100 ml) displayed significantly higher
levels of luminescent signal. These findings were confirmed by
sacrificing the mice immediately after imaging was completed to
determine the bacterial burdens in the lungs using standard
dilution plating techniques (Figure 2B).
To determine the impact of dose volume-dependent challenge
efficiencies on the course of experimental tularemic disease, we
performed a kinetic IVIS imaging analysis of BALB/c mice (3/
group) were anesthetized with inhaled isoflurane and then
challenged with 1610
6 FTLVS-lux using a range of instillation
volumes (10 ml, 20 ml, 50 ml, or 100 ml). Each mouse was subjected
to live whole-animal luminescent imaging at 24 hr intervals post
infection. These imaging studies revealed striking differences in
both the rate and tissue specificity of FT dissemination
(Figure 3A). At the 24-hour time point, the luminescence
emanating from the lungs of challenged mice confirmed that the
larger instillation volumes more efficiently delivered bacteria into
the lungs. By 48 hrs post-challenge, luminescent signatures were
detected in or around the upper airways of all of the animals. In
the mice that were challenged using a 10 ml volume, the
luminescent signature remained confined to the upper airways
over the entire timecourse, suggesting that the bacteria never
disseminated from the upper airways to the lungs, liver or spleen.
In contrast, the luminescent signatures observed in the lungs of
mice challenged using instillation volumes of 20 ml, 50 ml, and
100 ml increased in intensity over the timecourse. Moreover, the
infection appeared to disseminate from the lungs to the liver and
spleen in each of these experimental groups, and the rate of
dissemination increased with increasing instillation volume used to
administer intranasal challenge. Each mouse was also weighed
daily as an assessment of disease state. Weight retention results
confirmed that the dose volume used for intranasal instillation had
a significant impact on the course of tularemic disease (Figure 3B).
A significant difference (p,0.05) in weight retention between mice
that were dosed using a volume of 10 ml vs. 100 ml was observed as
early as 2 days post-infection, and by day 4 post-infection there
was a highly significant difference (p,0.001) between the 10 ml
volume group and each of the other experimental groups.
To examine the efficiency of intranasal dosing for pneumonic
delivery under differing forms of anesthesia, BALB/c mice (5/
group) that had been anesthetized with either parenteral
(ketamine/xylazine) or inhaled (isoflurane) anesthesia were
challenged with FTLVS-lux in an instillation volume of either
50 ml or 100 ml. IVIS imaging studies and lung bacterial burden
determinations were performed 24 hrs post-infection (Figure 4).
The intensity of luminescence emanating from the lungs of mice
challenged under inhaled anesthesia was more intense than
observed in mice anesthetized with parenterally-administered
ketamine/xylazine. The bacterial burden in the lungs was then
determined via dilution plating. Mice that were anesthetized using
inhaled isoflurane had significantly higher bacterial burdens in
their lungs than mice that had been anesthetized with parenteral
ketamine/xylazine (Figure 4), confirming the IVIS imaging
results.
Discussion
Intranasal instillation is the most widely used method for
delivery of drugs, vaccines, and/or infectious agents into the
respiratory tract of research mice. However, over the years there
have only been a handful of published studies designed to analyse
the efficiency of intranasal dosing. The primary variables that
should be considered when employing this technique are: i) type of
diluent used as vehicle for instillation, ii) physical positioning of the
Figure 1. Genetic Map of pXB173-lux. pXB173-lux constitutively
expresses the Photorhabdus luminescens luciferace (lux AB)a n d
luciferase substrate (luxCDE) from the Francisella groE promoter. This
vector also encodes a selectable marker for kanamycin resistance
(aph39).
doi:10.1371/journal.pone.0031359.g001
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the type of anesthesia used during instillation. Two of these
variables, namely instillation vehicle and physical positioning of
the mouse, were not considered in this report. Previously
published findings revealed that aqueous diluents were preferable
for intranasal instillation [19], therefore, PBS was used as the
vehicle for all of the experiments described herein. Moreover,
there have been several published studies in which positioning of
the mouse during intranasal instillation was considered, and while
some of the findings indicated that supine positioning was best for
promoting delivery of inocula to the lungs [19], other findings
suggested that positioning of the mouse did not have a significant
impact on pneumonic delivery efficiency [20]. Therefore, for all of
the studies reported here, mice were held in a tilted supine position
with their heads elevated to between 60 and 75 degrees above
their feet during and after (for approximately 1 minute) instilla-
tion.
Dose volume is the best characterized variable associated with
intranasal instillation. Published studies have evaluated instillation
volumes between 2 ml [21] and 100 ml [22]. Several reports used
either dyes or radioactive tracers to investigate the relative
efficiencies of various instillation volumes. Visweswaraiah and
colleagues performed instillations with Evan’s blue dye to evaluate
the efficiency of lung delivery using instillation volumes between
5 ml and 50 ml [23] and found that lower instillation volumes
resulted in retention of the inoculum in the URT while delivery of
dye to the lungs was accomplished only with the larger bolus
volumes. A similar study using a radioactive tracer (
99mTc-SC) also
concluded that instillation in a total volume of 5 ml resulted in
retention of the tracer in the URT with no detectable delivery to
the lungs [20]. This study also concluded that 35 ml was the
optimal instillation volume for delivery of tracer into the lungs.
Eyles and colleagues performed instillations of radiolabeled
microspheres in either 10 mlo r5 0ml volumes and found that
the radioactive microspheres accumulated in the URT when
delivered in the lower volume while approximately 50% of the
microspheres were delivered to the lungs when administered in the
larger volume [24]. Because we could find no studies in which
efficiency of pneumonic delivery via intranasal instillation was
tested using a bacterial agent, we performed a series of intranasal
instillation studies using luminescent FTLVS. Our findings were
consistent with those employing dyes or radioactive tracers and
confirmed that instillation in small volumes (10 ml) resulted in
delivery of FTLVS only to the URT while instillation in larger
volumes (50–100 ml) resulted in delivery of luminescent bacteria to
the lungs.
The use of anesthesia and the type of anesthesia used during
intranasal instillation is another variable that could have a
significant impact on its efficiency for delivery of inocula to the
lungs. It has been previously shown that delivery of materials to
the lungs via this technique is significantly more effective when
instillation of mice is performed under anesthesia during the
Figure 2. Correlation between whole animal in vivo imaging with viable bacterial counts 24 hours after challenge. BALB/c mice (5/
group) were challenged with 1610
6 CFU of FTLVS bearing the pXB173-lux reporter plasmid via the intranasal route in a total bolus volume of either
10 ml, 20 ml, 50 ml, or 100 ml. Panel A: Dissemination of FTLVS was then monitored 24 hrs later using an IVIS Spectrum whole animal imaging system.
Images were collected at the indicated time points post-infection and were normalized to reflect photons per second per cm‘2/sr. (Panel B): Lungs
were collected after imaging was completed for bacterial burden determination via dilution plating. Statistical analyses were performed via one-way
ANOVA using a Bonferroni multiple comparisons posttest. Statistically significant differences are indicated as follows: p,0.05 (*) and p,0.01 (**).
doi:10.1371/journal.pone.0031359.g002
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when intranasal instillation is performed on unanesthetized mice,
much of the instilled material was delivered to the gastrointestinal
tract suggesting that alert mice tend to swallow a significant portion
of the inoculum [23]. In light of these findings, and likely because
intranasal instillation is technically much easier to perform on
anesthetized mice, the majority of researchers using this technique
routinely anesthetize mice prior to the procedure. Therefore, it is
surprising that there has only been one other published study that
examined the effects of different types of anesthesia (parenteral vs.
inhaled) on the efficiency of this procedure for delivery of materials
to the lower respiratory tract (LRT) [20].
Figure 3. Kinetic in vivo localization of luminescent FTLVS following intranasal dosing in titrated volumes of inocula. BALB/c mice (3/
group) were challenged via the intranasal route with 1610
6 CFU of FTLVS-lux suspended in a volume of 10 ml, 20 ml, 50 ml, or 100 ml of sterile PBS.
Panel A: All mice were then subjected to whole animal imaging using an IVIS Spectrum Imaging system at the indicated time points. Scaling
intensity of all images was normalized and data are reported as photons/sec/cm‘2/sr. Panel B: All mice were weighed daily as a measure of disease-
state. Statistical analysis was performed via 2-way ANOVA with Bonferroni post-tests. Significant differences between the 10 ml instillation volume
group and all other groups are indicated toward the top of the graph and are color-coded. Significant differences between the 100 ml instillation
volume group and either the 20 mlo r5 0ml dose volume groups are indicated toward the bottom of the graph and are color-coded. The calculated p
values are indicated as follows: p,0.05 (*), p,0.01 (**), and p,0.001 (***).
doi:10.1371/journal.pone.0031359.g003
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for anesthesia in rodent-based research [25], we performed a
direct comparison of the efficiency of pneumonic delivery of
FTLVS-lux via intranasal instillation under these two types of
anesthesia. In light of our general observation that mice
anesthetized using parenteral-administered ketamine/xylazine
maintain a steadier breathing pattern than mice anesthetized for
relatively short periods using inhaled isoflurane, we hypothesized
that intranasal instillation would be more efficient for pulmonary
delivery of bacteria in mice that had been anesthetized with
ketamine/xylazine. To our surprise, delivery of bacteria to the
lungs was significantly more efficient when instillation was
Figure 4. Pulmonary delivery of FTLVS-lux was more efficient under inhaled vs. parenteral anesthesia. BALB/c mice (5/group) were
anesthetized using either inhaled isoflurane or parenterally-administered ketamine/xylazine and then challenged with either 1610
5 CFU FTLVS-lux in
a volume of 50 ml( Panel A)o r1 610
6 CFU FTLVS-lux in a volume of 100 ml( Panel B). Dissemination of FTLVS was monitored 24 hrs later using an
IVIS Spectrum whole animal imaging system. Lungs were collected after imaging was completed for bacterial burden determination via dilution
plating. All IVIS images were normalized to reflect photons per second per cm‘2/sr. Statistical analyses were performed using the student t test.
doi:10.1371/journal.pone.0031359.g004
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speculate that the irregular Cheyne-Stokes type respiratory pattern
that is typically observed following removal of mice from an
induction chamber with inhaled anesthesia causes transient
hypoxia which results in deeper inhalation of larger volumes of
inoculum per breath, facilitating more efficient delivery of the
material to the LRT. In contrast, mice that receive injectable
anesthesia breathe in a more-regular and more-shallow pattern,
resulting in a more-even coating of the URT surface with the
inoculum. Because the inoculum is more distributed along the
mucosal surface of the URT and the breathing pattern of the mice
is more shallow and regular, the inoculum is not delivered as
efficiently to the LRT. Our findings are in contrast to those from
the other published study that performed a comparison of inhaled
vs. parenteral anesthesia and concluded that the efficiency of
pulmonary delivery of intranasally instilled materials was not
impacted by the type of anesthesia [20].
It is relatively well established [20,23,24,26,27] that intranasal
instillation for the purpose of URT delivery requires a low
administration volume (#10 ml). However, no consensus has been
reached with respect to dose volume for delivery to the LRT. A
randomsurveyofveryrecentlypublished papersinwhichintranasal
instillation was employed for delivery of infectious agents (bacterial
and fungal pathogens) to the lungs of mice revealed that researchers
used a wide range of dose volumes in combination with a variety of
anesthesia types as follows: i) 20 ml instillation volume under
pentobarbital [28] or ketamine/xylazine anesthesia
[29,30,31,32,33], ii) 25 ml instillation volume under either pento-
barbital [34] or ketamine/xylazine anesthesia [35], iii) 30 ml
instillation volume under ketamine/xylazine anesthesia [36], iv)
35 ml instillation volume under ketamine/xylazine anesthesia [37],
v) 40 ml instillation volume under isoflurane anesthesia [38], vi)
50 ml instillation volume under either ketamine/xylazine [39],
isoflurane [40,41,42,43,44], halothane [45,46], and vii) 100 ml
instillation volume under isoflurane anesthesia [47]. Moreover, a
number of recent papers either supplied information regarding the
dose volume used without indicating the type of anesthesia [48,49],
indicated the anesthesia used but failed to indicate the dose volume
[50,51], or supplied no information regarding either the dose
volume or anesthesia [52,53,54] used for intranasal instillation.
The findings presented here have clearly shown that the
efficiency of pneumonic delivery via intranasal instillation is
significantly impacted by the volume of the inoculum as well as by
the type of anesthesia used during the procedure. These findings
underscore the importance of considering both variables when
comparing the experimental results between studies that involved
intranasal instillation for the purpose of delivering infectious agents
or other materials to the lungs. Therefore, it is critical that a
complete description of the methods used to anesthetize and
inoculate mice via intranasal instillation be supplied in any study
that employs this technique. Further studies are needed to
determine whether ‘‘high-volume’’ intranasal instillation has any
deleterious effects on research mice. The reference book entitled
‘‘The Mouse in Biomedical Research’’ states that intranasal
instillation in volumes greater than 20 ml can result in suffocation
and death of research mice [55]. While our findings do not support
this conclusion, we have noted brief respiratory distress in mice
that have received intranasal instillation volumes $50 ml.
Therefore, studies designed to evaluate respiratory function
before, during, and after intranasal instillation with a range of
instillation volumes are warranted. We are also initiating studies
that will determine whether instillation in larger volumes alters the
microenvironment of the lung enough to alter pneumonic disease
progression.
Materials and Methods
Bacterial Strains and Growth Conditions
F. tularensis strain LVS (live vaccine strain) was obtained from
the Centers for Disease Control and Prevention (CDC, Atlanta,
GA). F. tularensis was cultured in modified Mueller Hinton broth
(MMH broth supplemented with 10 g/L tryptone, 0.1% glucose,
0.025% ferrous pyrophosphate, 0.1% L-cysteine, and 2.5% calf
serum) or on MMH agar (supplemented with 5% calf serum and
1% IsoVitalex). FTLVS was transformed with the luminescence
reporter plasmid (pXB173-lux) as described previously [18].
Kanamycin (km) was used at 10 mg/mL to maintain selection
for FTLVS bearing the lux-reporter plasmid. We received
authorization from the CDC, the Department of Health and
Human Services, and from the University of Tennessee Health
Science Center (UTHSC) Institutional Biosafety Committee for
the use of aph39 in FT.
Mice
Female BALB/c mice were purchased from either Jackson
Laboratories or Charles River Laboratories. Mice were age-
matched and used between 8 and 16 weeks of age. Mice were
housed in an AALAC accredited facility in microisolator cages
with food and water available ad libitum. All experimental protocols
were reviewed and approved by the UTHSC IACUC.
Anesthesia and Intranasal Instillation
Prior to instillation, mice were anesthetized using either inhaled
(isoflurane) or parenteral (ketamine/xylazine) anesthesia. Isoflur-
ane was delivered using a SurgiVetH Vaporstick small animal
anesthesia machine equipped with a Classic T3
TM isoflurane
vaporizer (Smith Medical, Dublin, OH) and mice were exposed to
2.5% isoflurane delivered in O2 (2 L/min) within a 1 liter
induction chamber until a state of areflexia was reached.
Ketamine (KetaVed, VEDCO, St. Joseph, MO; 9 mg/10 g body
weight) and xylazine (AnaSed, Lloyd Laboratories, Shenandoah,
IA; 1 mg/g body weight) were administered intraperitoneally and
mice were challenged once a stable plane of anesthesia was
reached. Intranasal administration of each challenge dose was
performed by pipetting approximately half of the designated
volume of PBS (containing the indicated number of FTLVS) onto
the outer edge of each nare of the mice. Mice receiving isoflurane
anesthesia were removed from the induction chamber and
instillation was performed immediately; no supplemental anesthe-
sia or oxygen was administered following removal from the
induction chamber.
Whole-Animal Luminescent Imaging
The photon emissions from mice that had been infected with
FTLVS-lux were measured using an IVIS Spectrum whole live-
animal imaging system (Caliper Life Sciences, Hopkinton, MA).
Mice were anesthetized with isoflurane using a precision vaporizer
and oxygen before and during imaging. Images were collected
using medium binning with an F-stop of 1, and the maximum
exposure time was 5 minutes. The luminescent signals for all
images in any individual study were normalized and reported as
photons/second/cm‘2/sr.
Bacterial Burden Determination
Lungs of challenged mice were removed aseptically and
homogenized (using a closed tissue grinder system, Fisher
Scientific, Pittsburgh, PA) in one ml of sterile PBS, and the final
volume was adjusted to 1.25 ml with PBS. To disrupt cells
(releasing FT), 0.25 ml disruption buffer (2.5% saponin, 15%
Pneumonic Delivery via Intranasal Instillation
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dilutions of each sample were then plated in duplicate using an
Eddy Jet spiral plater (Neutec Group Inc., Farmingdale, NY) on
MMH agar plates and incubated at 37uC for 48–72 hours.
Colonies were counted using a Flash & Go automated colony
counter (Neutec Group Inc.).
Statistical Methodology
Statistical analyses of each figure were performed using
GraphPad Prism software (GraphPad Software, La Jolla, CA).
The specific statistical method used for each dataset is described in
the figure legends.
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